Liquid Biopsy Market
Liquid Biopsy Market by Marker Type, Sample Type, Application Type & Region | Forecast 2022 to 2032
Peruse FMIs Liquid Biopsy Market Analysis, complete with up-to-date Growth Trends
Liquid Biopsy Market Snapshot (2022 to 2032)
Global liquid biopsy market demand is anticipated to be valued at US$ 1,146 Million in 2022, forecast a CAGR of 13.49% to be valued at US$ 4,126 Million from 2022 to 2032. Growth is attributed to increasing cancer incidences and low treatment rates.
|
Data Points |
Key Statistics |
|
Projected Growth Rate (2022 to 2032) |
13.49% CAGR |
|
Expected Market Value (2022) |
US$ 1,146 Million |
|
Anticipated Forecast Value (2032) |
US$ 4,126 Million |
A liquid biopsy is a non-invasive procedure to surgical biopsies which helps to discover a tumor through a simple blood sample. Traces of cancer's DNA in the blood can give clues about which treatments are most likely to work for that patient.
Liquid biopsies are used for diagnosing non-small cell lung cancer (NSCLC) and screening or as a companion diagnostic for other types of cancers such as gastrointestinal, colorectal, breast, prostate, and ovarian cancer.
The cost-effectiveness and high efficacy of liquid biopsy over other diagnostic tests are chief factors responsible for market growth. Fast-track approvals from regulatory bodies such as the USA Food and Drug Administration (FDA) for non-invasive cancer diagnosis tests will continue creating growth opportunities.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Which are Some Prominent Drivers Spearheading Liquid Biopsy Market Growth?
Government Initiatives to boost the Liquid Biopsy Market Growth
Cancer has been affecting humanity for decades, and the numbers continue to rise even with the emergence of better treatment and care. In 2020, the World Health Organization (WHO) reported nearly 10 million deaths caused due to cancer. This staggering rise in number emphasizes on the need for accurate and convenient cancer diagnostic systems for early detection.
Governments in various high-cancer-burden nations have pledged to assist cancer research by providing adequate funds that can aid in improved outcomes. For instance, as per the National Institute of Health (NIH), the federal government has allocated US$ 119 Million to National Cancer Institute for the fiscal year 2021.
Similarly, in 2018, India-United Kingdom Cancer Research Initiative came into effect which focused on improved and affordable approaches to cancer diagnosis and treatment. The initiative will receive investments valued at £5 Million from the Department of Biotechnology (DBT), Ministry of Science & Technology, India, and Cancer Research United Kingdom (CRUK) each over a 5-year program.
These government-led initiatives will further promote cancer specialists across the globe to set research goals aimed at affordability, convenience, and optimal patient care in cancer treatments. Adequate funding will allow experts to develop research alliances to enable significant improvements against numerous cancer outcomes.
What are the Challenges Faced by the Liquid Biopsy Industry?
Although the liquid biopsy market has numerous end-uses, there are numerous obstacles that likely pose a challenge to market growth. The lack of skilled professionals required to operate instruments is a major factor that can restrain the growth of the market for liquid biopsy. Also, the blood Collection in liquid biopsy is a sensitive technique, and negligence in operation or lack of skill can ruin the process. Such techniques require highly qualified and trained professionals who understand the technology and mechanism.
Find your sweet spots for generating winning opportunities in this market.
Why is North America Emerging as an Opportunistic Liquid Biopsy Market?
In terms of market share and revenue, the North American market is predicted to be the most lucrative market for liquid biopsy during the forecast period, 2022 and 2032.
One of the primary factors propelling the diagnostics industry in the region is the presence of various biotechnology and medical device firms. North America is likely to maintain its lead during the projection period due to factors such as increased spending for Research and Development initiatives and widespread use of new technology.
How will the Liquid Biopsy Market Expand in the USA?
As per FMI’s analysis, the USA is projected to account for 51% of the total market share in the liquid biopsy market during the assessment period. Growth prospects in the United States of America can be attributed to increasing government funding to support cancer research. The rising prevalence of cancer across the United States of America will generate high demand for highly accurate liquid biopsy services.
Wide adoption of technological developments including artificial intelligence, machine learning, and microchip-based liquid biopsy diagnostic services will lead to market expansion in the United States of America
In addition to this, the presence of major players including Biocept Inc., Janssen Global Services, and Trovagene Inc., will further lead to innovation in liquid biopsy technologies and procedures. Thereby, creating remunerative opportunities in the liquid biopsy market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
How Will the Growth of the European Liquid Biopsy Market Unfold?
The European liquid biopsy market is predicted to increase significantly throughout the forecast period, due to the desirable healthcare policies, along with high average per capita healthcare costs, which have produced a favorable climate in the United Kingdom for the adoption of modern cancer diagnostic technology.
What is the Scope of Liquid Biopsy Market Growth in The United Kingdom?
As per a report by Macmillan Cancer Support, the number of cancer patients is estimated to reach 4 million by 2030. A foreseeable spike in cancer cases will underscore the need for liquid biopsy to actively diagnose patients for early treatment and care.
The presence of several well-known research institutes in the United Kingdom such as the University of Oxford and the National Institute of Medical Research will further lead to developments in liquid biopsy services.
These developments will provide lucrative opportunities for players operating in the market, allowing them to benefit from technological advancements for better products and services. The United Kingdom will account for 24% of the market share, as estimated by FMI.
Will the Asia Pacific emerge as an Attractive Liquid Biopsy Market?
The increased awareness among people about the benefits of liquid biopsy is contributing to the growth of the region as the Asia Pacific area is expected to be one of the emerging economies for cancer diagnostics. Due to the existence of a big patient pool, the availability of experienced technicians at a reduced cost, and a clear regulatory environment encouraging quicker product approvals, Asia Pacific is likely to display the strongest growth in the near future. Furthermore, the burgeoning medical tourism business in countries like China, India, and Malaysia is likely to increase demand for liquid biopsy in the region.
How will Japan Emerge as A Lucrative Market?
As per a recent report by the Japan Agency of Medical Research and Development, the country has launched ‘CIRCULATE-Japan’, a research project to analyze cancer treatments through a liquid biopsy for testing circulating tumor DNA in the blood of patients suffering from colorectal cancer.
The research project is mainly launched to derive the clinical advantages of risk assessment of tumors through a liquid biopsy for ‘invisible cancers’. With the increasing incidence of cancer in the country, it focuses on developing convenient and accurate diagnosis procedures is on the rise. These trends are anticipated to provide tailwinds to demand liquid biopsy services as a ripple effect.
What Are the Growth Prospects for Liquid Biopsy Market in India?
Government initiatives aimed at improving cancer awareness, research, and development are anticipated to propel the growth of the liquid biopsy market in India, as per FMI's market survey. As revealed by the National Cancer Registry, cancer incidence in men is estimated to reach 736,575 in 2025, with 806,218 cases to be recorded in women.
An increasing number of cancer cases is anticipated to underscore the pressing need for technologically advanced liquid biopsy systems, which in turn will shape the demand outlook in the country.
Additionally, numerous budding and established biotech companies in India are focusing on research and development for early diagnosis and improvements in cancer treatment and patient care. Such developments will provide opportunities for market expansion to major global players, thereby propelling sales in India.
Startup Scenario
The new entrants in the liquid biopsy market are continually indulging in several collaborations and highly investing in research and development activities to provide more convenient solutions to industry verticals. Some of the major start-ups that are leading the development of the market are- Strand Life Sciences, DNA Labs India, and Onco Discover.
- Strand Life Sciences is a clinical research and diagnostics company that combines a long track record in bioinformatics with cutting-edge laboratory assays and a vast hospital partner network to drive newer generations of patient care. Strand Life Sciences announced an agreement to acquire the India medical diagnostics business of Quest Diagnostics, the world’s leading provider of diagnostic information services.
Market Competition
Key players in the liquid biopsy market are aiming at strategic collaborations with end-users including hospitals, diagnostic centers, and cancer research institutes to strengthen their product offerings in the market. As per FMI analysis, tier-1 players will account for approximately 20-25% of the total sales.
Industry research funding and product development agreements will provide proprietary benefits to manufacturers, helping them contribute to the development of accurate diagnosis methods for various cancers. In addition, gaining patents and government approvals for new technologies will remain one of the prominent growth strategies. For instance:
- In July 2021, Biocept Inc., one of the leading providers of molecular diagnostic services, received a South Korean Patent for its newly launched Primer-Switch technology. Primer-Switch technology detects mutations in circulating tumor DNA (ctDNA) using real-time PCR and related methods, identifying rare cancer biomarkers.
- In July 2021, Janssen Global Services, LLC, received FDA approval for DARZALEX FASPRO in combination with pomalidomide and dexamethasone (Pd) for treating adult patients with multiple myeloma, further strengthening the company’s product offerings.
Report Scope
|
Report Attribute |
Details |
|
Growth Rate |
CAGR of 13.49% from 2022 to 2032 |
|
Expected Market Value (2022) |
US$ 1,146 Million |
|
Anticipated Forecast Value (2032) |
US$ 4,126 Million |
|
Base Year for Estimation |
2021 |
|
Historical Data |
2016 to 2021 |
|
Forecast Period |
2022 to 2032 |
|
Quantitative Units |
Revenue in USD Billion and CAGR from 2022 to 2032 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Liquid Biopsy Industry Survey
Liquid Biopsy Market by Marker Type:
- CTCs (Circulating Tumour Cells)
- ctNA (Circulating tumor Nucleic Acids)
- Exosomes
Liquid Biopsy Market by Sample Type:
- Blood Liquid Biopsy
- Urine Liquid Biopsy
- Other (Plasma, Saliva, CSF) Liquid Biopsy
Liquid Biopsy Market by Application Type:
- Liquid Biopsy for Lung Cancer
- Liquid Biopsy for Gastrointestinal Cancer
- Liquid Biopsy for Prostate Cancer
- Liquid Biopsy for Breast Cancer
- Liquid Biopsy for Colorectal Cancer
- Liquid Biopsy for Leukemia
Liquid Biopsy Market by Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific Excluding Japan
- Japan
- Middle East and Africa
Frequently Asked Questions
What is the anticipated growth of the liquid biopsy market until 2032?
FMI projects the global liquid biopsy market to expand at a 13.49% value CAGR by 2032
Which country is forecast to be the most lucrative for liquid Biopsy market growth?
The USA is expected to be the most opportunistic with a 51% share of the total liquid biopsy market
Which are some prominent liquid biopsy market manufacturers?
BIOCEPT, INC., Qiagen N.V., Trovagene, Inc, Janssen Global Services, LLC, MDxHealth SA, and Natera, Inc are some prominent liquid biopsy, market manufacturers.
Table of Content
1. Executive Summary | Liquid Biopsy Market 2. Assumptions and Acronyms 3. Research Methodology 4. Market Overview 4.1. Introduction 4.1.1. Market Definition 4.1.2. Market Taxonomy 4.2. Market Dynamics 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunity 4.3. Regional Cancer Epidemiology 4.4. Reimbursement Scenario 4.5. Pipeline Assessment, By Products 4.6. Product Penetration and Pricing Impact 4.7. Revenue Potential Liquid Biopsy 4.8. Case Studies 5. Global Market Forecast 5.1. Market Value (US$ Million) Forecast 5.1.1. Y-o-Y Growth Projections 5.1.2. Absolute $ Opportunity 5.2. Market Trends 5.3. Global Market Snapshot (2015) 5.3.1. Market Share, By Sample Type 5.3.2. Market Share, By Disease Indication 5.3.3. Market Share, By Marker Type 5.3.4. Market Share, By End User 6. Global Market Analysis, By Sample Type 6.1. Introduction 6.1.1. Y-o-Y Growth Comparison, By Sample Type 6.1.2. Market Share & Basis Point (BPS) Analysis, By Sample Type 6.2. Market Forecast, By Sample Type 6.2.1. Blood 6.2.1.1. Absolute $ Opportunity 6.2.1.2. Market Value (US$ Million) Forecast 6.2.2. Urine 6.2.2.1. Absolute $ Opportunity 6.2.2.2. Market Value (US$ Million) Forecast 6.2.3. Others (Plasma, Saliva, CSF) 6.2.3.1. Absolute $ Opportunity 6.2.3.2. Market Value (US$ Million) Forecast 6.3. Market Attractiveness Analysis, By Sample Type 7. Global Market Analysis, By Marker Type 7.1. Introduction 7.1.1. Y-o-Y Growth Comparison, By Marker Type 7.1.2. Market Share & Basis Point (BPS) Analysis, By Marker Type 7.2. Market Forecast, By Marker Type 7.2.1. CTCs (circulating tumor cells) 7.2.1.1. Absolute $ Opportunity 7.2.1.2. Market Value (US$ Million) Forecast 7.2.2. ctNA (circulating tumor nucleic acids) 7.2.2.1. Absolute $ Opportunity 7.2.2.2. Market Value (US$ Million) Forecast 7.2.3. Exosomes 7.2.3.1. Absolute $ Opportunity 7.2.3.2. Market Value (US$ Million) Forecast 7.3. Market Attractiveness Analysis, By Marker Type 8. Global Market Analysis, By End User 8.1. Introduction 8.1.1. Y-o-Y Growth Comparison, By End User 8.1.2. Market Share & Basis Point (BPS) Analysis, By End User 8.2. Market Forecast, By End User 8.2.1. Hospitals 8.2.1.1. Absolute $ Opportunity 8.2.1.2. Market Value (US$ Million) Forecast 8.2.2. Academic Institutes 8.2.2.1. Absolute $ Opportunity 8.2.2.2. Market Value (US$ Million) Forecast 8.2.3. Cancer Institutes 8.2.3.1. Absolute $ Opportunity 8.2.3.2. Market Value (US$ Million) Forecast 8.2.4. Diagnostic Centers 8.2.4.1. Absolute $ Opportunity 8.2.4.2. Market Value (US$ Million) Forecast 8.3. Market Attractiveness Analysis, By End User 9. Global Market Analysis, By Disease Indication 9.1. Introduction 9.1.1. Y-o-Y Growth Comparison, By Disease Indication 9.1.2. Market Share & Basis Point (BPS) Analysis, By Disease Indication 9.2. Market Forecast, By Disease Indication 9.2.1. Lung Cancer 9.2.1.1. Absolute $ Opportunity 9.2.1.2. Market Value (US$ Million) Forecast 9.2.2. Leukemia 9.2.2.1. Absolute $ Opportunity 9.2.2.2. Market Value (US$ Million) Forecast 9.2.3. Gastrointestinal Cancer 9.2.3.1. Absolute $ Opportunity 9.2.3.2. Market Value (US$ Million) Forecast 9.2.4. Breast Cancer 9.2.4.1. Absolute $ Opportunity 9.2.4.2. Market Value (US$ Million) Forecast 9.2.5. Prostate Cancer 9.2.5.1. Absolute $ Opportunity 9.2.5.2. Market Value (US$ Million) Forecast 9.2.6. Colorectal Cancer 9.2.6.1. Absolute $ Opportunity 9.2.6.2. Market Value (US$ Million) Forecast 9.2.7. Others 9.2.7.1. Absolute $ Opportunity 9.2.7.2. Market Value (US$ Million) Forecast 9.3. Market Attractiveness Analysis, By Disease Indication 10. Global Market Analysis, By Region 10.1. Introduction 10.1.1. Y-o-Y Growth Projections, By Region 10.1.2. Market Share & Basis Point (BPS) Analysis, By Region 10.2. Market Forecast, By Region 10.2.1. North America Market Value (US$ Million) Forecast 10.2.2. Latin America Market Value (US$ Million) Forecast 10.2.3. Western Europe Market Value (US$ Million) Forecast 10.2.4. Eastern Europe Market Value (US$ Million) Forecast 10.2.5. APEJ Market Value (US$ Million) Forecast 10.2.6. Japan Market Value (US$ Million) Forecast 10.2.7. Middle East and Africa Market Value (US$ Million) Forecast 10.3. Regional Attractiveness Analysis 11. North America Market Analysis 11.1. Introduction 11.1.1. Y-o-Y Growth Projections, By Country 11.1.2. Market Share & Basis Point (BPS) Analysis, By Country 11.2. Key Trends 11.3. North America Market Forecast 11.3.1. Market Value (US$ Million) Forecast, By Country 11.3.1.1. USA Absolute $ Opportunity 11.3.1.2. Canada Absolute $ Opportunity 11.3.2. Market Value (US$ Million) Forecast, By Sample Type 11.3.2.1. Blood 11.3.2.2. Urine 11.3.2.3. Others (Plasma, Saliva, CSF) 11.3.3. Market Value (US$ Million) Forecast, By Marker Type 11.3.3.1. CTCs (circulating tumor cells) 11.3.3.2. ctNA (circulating tumor nucleic acids) 11.3.3.3. Exosomes 11.3.4. Market Value (US$ Million) Forecast, By End User 11.3.4.1. Hospitals 11.3.4.2. Academic Institutes 11.3.4.3. Cancer Institutes 11.3.4.4. Diagnostic Centers 11.3.5. Market Value (US$ Million) Forecast, By Disease Indication 11.3.5.1. Lung Cancer 11.3.5.2. Leukemia 11.3.5.3. Gastrointestinal Cancer 11.3.5.4. Breast Cancer 11.3.5.5. Prostate Cancer 11.3.5.6. Colorectal Cancer 11.3.5.7. Others 11.4. Market Attractiveness Analysis 11.4.1. By Country 11.4.2. By Sample Type 11.4.3. By Disease Indication 11.4.4. By Marker Type 11.4.5. By End User 11.5. Drivers & Restraints: Impact Analysis 12. Latin America Market Analysis 12.1. Introduction 12.1.1. Y-o-Y Growth Projections, By Country 12.1.2. Market Share & Basis Point (BPS) Analysis, By Country 12.2. Key Trends 12.3. Latin America Market Forecast 12.3.1. Market Value (US$ Million) Forecast, By Country 12.3.1.1. Brazil Absolute $ Opportunity 12.3.1.2. Mexico Absolute $ Opportunity 12.3.1.3. Rest of Latin America Absolute $ Opportunity 12.3.2. Market Value (US$ Million) Forecast, By Sample Type 12.3.2.1. Blood 12.3.2.2. Urine 12.3.2.3. Others (Plasma, Saliva, CSF) 12.3.3. Market Value (US$ Million) Forecast, By Marker Type 12.3.3.1. CTCs (circulating tumor cells) 12.3.3.2. ctNA (circulating tumor nucleic acids) 12.3.3.3. Exosomes 12.3.4. Market Value (US$ Million) Forecast, By End User 12.3.4.1. Hospitals 12.3.4.2. Academic Institutes 12.3.4.3. Cancer Institutes 12.3.4.4. Diagnostic Centers 12.3.5. Market Value (US$ Million) Forecast, By Disease Indication 12.3.5.1. Lung Cancer 12.3.5.2. Leukemia 12.3.5.3. Gastrointestinal Cancer 12.3.5.4. Breast Cancer 12.3.5.5. Prostate Cancer 12.3.5.6. Colorectal Cancer 12.3.5.7. Others 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Sample Type 12.4.3. By Disease Indication 12.4.4. By Marker Type 12.4.5. By End User 12.5. Drivers & Restraints: Impact Analysis 13. Western Europe Market Analysis 13.1. Introduction 13.1.1. Y-o-Y Growth Projections, By Country 13.1.2. Market Share & Basis Point (BPS) Analysis, By Country 13.2. Key Trends 13.3. Western Europe Market Forecast 13.3.1. Market Value (US$ Million) Forecast, By Country 13.3.1.1. Germany Absolute $ Opportunity 13.3.1.2. France Absolute $ Opportunity 13.3.1.3. United Kingdom Absolute $ Opportunity 13.3.1.4. Spain Absolute $ Opportunity 13.3.1.5. Italy Absolute $ Opportunity 13.3.1.6. Rest of Western Europe Absolute $ Opportunity 13.3.2. Market Value (US$ Million) Forecast, By Sample Type 13.3.2.1. Blood 13.3.2.2. Urine 13.3.2.3. Others (Plasma, Saliva, CSF) 13.3.3. Market Value (US$ Million) Forecast, By Marker Type 13.3.3.1. CTCs (circulating tumor cells) 13.3.3.2. ctNA (circulating tumor nucleic acids) 13.3.3.3. Exosomes 13.3.4. Market Value (US$ Million) Forecast, By End User 13.3.4.1. Hospitals 13.3.4.2. Academic Institutes 13.3.4.3. Cancer Institutes 13.3.4.4. Diagnostic Centers 13.3.5. Market Value (US$ Million) Forecast, By Disease Indication 13.3.5.1. Lung Cancer 13.3.5.2. Leukemia 13.3.5.3. Gastrointestinal Cancer 13.3.5.4. Breast Cancer 13.3.5.5. Prostate Cancer 13.3.5.6. Colorectal Cancer 13.3.5.7. Others 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Sample Type 13.4.3. By Disease Indication 13.4.4. By Marker Type 13.4.5. By End User 13.5. Drivers & Restraints: Impact Analysis 14. Eastern Europe Market Analysis 14.1. Introduction 14.1.1. Y-o-Y Growth Projections, By Country 14.1.2. Market Share & Basis Point (BPS) Analysis, By Country 14.2. Key Trends 14.3. Eastern Europe Market Forecast 14.3.1. Market Value (US$ Million) Forecast, By Country 14.3.1.1. Russia Absolute $ Opportunity 14.3.1.2. Poland Absolute $ Opportunity 14.3.1.3. Rest of Eastern Europe Absolute $ Opportunity 14.3.2. Market Value (US$ Million) Forecast, By Sample Type 14.3.2.1. Blood 14.3.2.2. Urine 14.3.2.3. Others (Plasma, Saliva, CSF) 14.3.3. Market Value (US$ Million) Forecast, By Marker Type 14.3.3.1. CTCs (circulating tumor cells) 14.3.3.2. ctNA (circulating tumor nucleic acids) 14.3.3.3. Exosomes 14.3.4. Market Value (US$ Million) Forecast, By End User 14.3.4.1. Hospitals 14.3.4.2. Academic Institutes 14.3.4.3. Cancer Institutes 14.3.4.4. Diagnostic Centers 14.3.5. Market Value (US$ Million) Forecast, By Disease Indication 14.3.5.1. Lung Cancer 14.3.5.2. Leukemia 14.3.5.3. Gastrointestinal Cancer 14.3.5.4. Breast Cancer 14.3.5.5. Prostate Cancer 14.3.5.6. Colorectal Cancer 14.3.5.7. Others 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Sample Type 14.4.3. By Disease Indication 14.4.4. By Marker Type 14.4.5. By End User 15. APEJ Market Analysis 15.1. Introduction 15.1.1. Y-o-Y Growth Projections, By Country 15.1.2. Market Share & Basis Point (BPS) Analysis, By Country 15.2. Key Trends 15.3. APEJ Market Forecast 15.3.1. Market Value (US$ Million) Forecast, By Country 15.3.1.1. China Absolute $ Opportunity 15.3.1.2. India Absolute $ Opportunity 15.3.1.3. Australia & New Zealand Absolute $ Opportunity 15.3.1.4. ASEAN Absolute $ Opportunity 15.3.1.5. Rest of APEJ Absolute $ Opportunity 15.3.2. Market Value (US$ Million) Forecast, By Sample Type 15.3.2.1. Blood 15.3.2.2. Urine 15.3.2.3. Others (Plasma, Saliva, CSF) 15.3.3. Market Value (US$ Million) Forecast, By Marker Type 15.3.3.1. CTCs (circulating tumor cells) 15.3.3.2. ctNA (circulating tumor nucleic acids) 15.3.3.3. Exosomes 15.3.4. Market Value (US$ Million) Forecast, By End User 15.3.4.1. Hospitals 15.3.4.2. Academic Institutes 15.3.4.3. Cancer Institutes 15.3.4.4. Diagnostic Centers 15.3.5. Market Value (US$ Million) Forecast, By Disease Indication 15.3.5.1. Lung Cancer 15.3.5.2. Leukemia 15.3.5.3. Gastrointestinal Cancer 15.3.5.4. Breast Cancer 15.3.5.5. Prostate Cancer 15.3.5.6. Colorectal Cancer 15.3.5.7. Others 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Sample Type 15.4.3. By Disease Indication 15.4.4. By Marker Type 15.4.5. By End User 15.5. Drivers & Restraints: Impact Analysis 16. Japan Market Analysis 16.1. Introduction 16.2. Key Trends 16.3. Japan Market Forecast 16.3.1. Market Value (US$ Million) Forecast, By Sample Type 16.3.1.1. Blood 16.3.1.2. Urine 16.3.1.3. Others (Plasma, Saliva, CSF) 16.3.2. Market Value (US$ Million) Forecast, By Marker Type 16.3.2.1. CTCs (circulating tumor cells) 16.3.2.2. ctIndication (circulating tumor nucleic acids) 16.3.2.3. Exosomes 16.3.3. Market Value (US$ Million) Forecast, By End User 16.3.3.1. Hospitals 16.3.3.2. Academic Institutes 16.3.3.3. Cancer Institutes 16.3.3.4. Diagnostic Centers 16.3.4. Market Value (US$ Million) Forecast, By Disease Indication 16.3.4.1. Lung Cancer 16.3.4.2. Leukemia 16.3.4.3. Gastrointestinal Cancer 16.3.4.4. Metastatic Breast Cancer 16.3.4.5. Metastatic Prostate Cancer 16.3.4.6. Metastatic Colorectal Cancer 16.3.4.7. Others 16.4. Market Attractiveness Analysis 16.4.1. By Sample Type 16.4.2. By Disease Indication 16.4.3. By Marker Type 16.4.4. By End User 16.5. Drivers & Restraints: Impact Analysis 17. Middle East and Africa Market Analysis 17.1. Introduction 17.1.1. Y-o-Y Growth Projections, By Country 17.1.2. Market Share & Basis Point (BPS) Analysis, By Country 17.2. Key Trends 17.3. Middle East and Africa Market Forecast 17.3.1. Market Value (US$ Million) Forecast, By Country 17.3.1.1. GCC Countries Absolute $ Opportunity 17.3.1.2. South Africa Absolute $ Opportunity 17.3.1.3. Rest of MEA Absolute $ Opportunity 17.3.2. Market Value (US$ Million) Forecast, By Sample Type 17.3.2.1. Blood 17.3.2.2. Urine 17.3.2.3. Others (Plasma, Saliva, CSF) 17.3.3. Market Value (US$ Million) Forecast, By Marker Type 17.3.3.1. CTCs (circulating tumor cells) 17.3.3.2. ctNA (circulating tumor nucleic acids) 17.3.3.3. Exosomes 17.3.4. Market Value (US$ Million) Forecast, By End User 17.3.4.1. Hospitals 17.3.4.2. Academic Institutes 17.3.4.3. Cancer Institutes 17.3.4.4. Diagnostic Centers 17.3.5. Market Value (US$ Million) Forecast, By Disease Indication 17.3.5.1. Lung Cancer 17.3.5.2. Leukemia 17.3.5.3. Gastrointestinal Cancer 17.3.5.4. Metastatic Breast Cancer 17.3.5.5. Metastatic Prostate Cancer 17.3.5.6. Metastatic Colorectal Cancer 17.3.5.7. Others 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Sample Type 17.4.3. By Disease Indication 17.4.4. By Marker Type 17.4.5. By End User 17.5. Drivers & Restraints: Impact Analysis 18. Competition Landscape 18.1. Competition Dashboard 18.2. Company Profiles Inclusions 18.2.1. Revenue 18.2.2. Products/Brand Offerings 18.2.3. Key developments 18.2.4. SWOT Analysis 18.3. Company Profiled 18.3.1. BIOCEPT, INC. 18.3.1.1. Revenue 18.3.1.2. Products/Brand Offerings 18.3.1.3. Key developments 18.3.1.4. SWOT Analysis 18.3.2. Qiagen N.V. 18.3.2.1. Revenue 18.3.2.2. Products/Brand Offerings 18.3.2.3. Key developments 18.3.2.4. SWOT Analysis 18.3.3. Trovagene, Inc 18.3.3.1. Revenue 18.3.3.2. Products/Brand Offerings 18.3.3.3. Key developments 18.3.3.4. SWOT Analysis 18.3.4. Janssen Global Services, LLC 18.3.4.1. Revenue 18.3.4.2. Products/Brand Offerings 18.3.4.3. Key developments 18.3.4.4. SWOT Analysis 18.3.5. MDxHealth SA 18.3.5.1. Revenue 18.3.5.2. Products/Brand Offerings 18.3.5.3. Key developments 18.3.5.4. SWOT Analysis 18.3.6. Natera, Inc 18.3.6.1. Revenue 18.3.6.2. Products/Brand Offerings 18.3.6.3. Key developments 18.3.6.4. SWOT Analysis 18.3.7. F. Hoffmann-La Roche Ltd 18.3.7.1. Revenue 18.3.7.2. Products/Brand Offerings 18.3.7.3. Key developments 18.3.7.4. SWOT Analysis 18.3.8. Silicon Biosystems 18.3.8.1. Revenue 18.3.8.2. Products/Brand Offerings 18.3.8.3. Key developments 18.3.8.4. SWOT Analysis 18.3.9. Pathway Genomics Corporation 18.3.9.1. Revenue 18.3.9.2. Products/Brand Offerings 18.3.9.3. Key developments 18.3.9.4. SWOT Analysis 18.3.10. Sysmex Corporation 18.3.10.1. Revenue 18.3.10.2. Products/Brand Offerings 18.3.10.3. Key developments 18.3.10.4. SWOT Analysis
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 01: Global Market Value Forecast By Sample Type, 2022 to 2032 Table 02: Global Market Value Forecast By Marker Type, 2022 to 2032 Table 03: Global Market Value Forecast By End User, 2022 to 2032 Table 04: Global Market Value Forecast By Disease Indication, 2022 to 2032 Table 05: Global Market Value Forecast By Region, 2022 to 2032 Table 06: North America Market Value Forecast By Country, 2022 to 2032 Table 07: North America Market Value Forecast By Sample Type, 2022 to 2032 Table 08: North America Market Value Forecast By Marker Type, 2022 to 2032 Table 09: North America Market Value Forecast By End User, 2022 to 2032 Table 10: North America Market Value Forecast By Disease Indication, 2022 to 2032 Table 11: Latin America Market Value Forecast By Country, 2022 to 2032 Table 12: Latin America Market Value Forecast By Sample Type, 2022 to 2032 Table 13: Latin America Market Value Forecast By Marker Type, 2022 to 2032 Table 14: Latin America Market Value Forecast By End User, 2022 to 2032 Table 15: Latin America Market Value Forecast By Disease Indication, 2022 to 2032 Table 16: Western Europe Market Value Forecast By Country, 2022 to 2032 Table 17: Western Europe Market Value Forecast By Sample Type, 2022 to 2032 Table 18: Western Europe Market Value Forecast By Marker Type, 2022 to 2032 Table 19: Western Europe Market Value Forecast By End User, 2022 to 2032 Table 20: Western Europe Market Value Forecast By Disease Indication, 2022 to 2032 Table 21: Eastern Europe Market Value Forecast By Country, 2022 to 2032 Table 22: Eastern Europe Market Value Forecast By Sample Type, 2022 to 2032 Table 23: Eastern Europe Market Value Forecast By Marker Type, 2022 to 2032 Table 24: Eastern Europe Market Value Forecast By End User, 2022 to 2032 Table 25: Eastern Europe Market Value Forecast By Disease Indication, 2022 to 2032 Table 26: APEJ Market Value Forecast By Country, 2022 to 2032 Table 27: APEJ Market Value Forecast By Sample Type, 2022 to 2032 Table 28: APEJ Market Value Forecast By Marker Type, 2022 to 2032 Table 29: APEJ Market Value Forecast By End User, 2022 to 2032 Table 30: APEJ Market Value Forecast By Disease Indication, 2022 to 2032 Table 31: Japan Market Value Forecast By Sample Type, 2022 to 2032 Table 32: Japan Market Value Forecast By Marker Type, 2022 to 2032 Table 33: Japan Market Value Forecast By End User, 2022 to 2032 Table 34: Japan Market Value Forecast By Disease Indication, 2022 to 2032 Table 35: MEA Market Value Forecast By Country, 2022 to 2032 Table 36: MEA Market Value Forecast By Sample Type, 2022 to 2032 Table 37: MEA Market Value Forecast By Marker Type, 2022 to 2032 Table 38: MEA Market Value Forecast By End User, 2022 to 2032 Table 39: MEA Market Value Forecast By Disease Indication, 2022 to 2032
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 01: Global Market Share Analysis (%) By Sample Type, 2022 & 2032 Figure 02: Global Market Y-o-Y Growth (%) By Sample Type, 2022 to 2032 Figure 03: Global Market Attractiveness Analysis By Sample Type, 2022 to 2032 Figure 04: Global Market Value (US$ Million) & Y-o-Y Growth (%) By Blood Sample Type Segment, 2022 to 2032 Figure 05: Global Market Absolute $ Opportunity (US$ Million) By Blood Sample Type Segment, 2022 to 2032 Figure 06: Global Market Value (US$ Million) & Y-o-Y Growth (%) By Urine Sample Type Segment, 2022 to 2032 Figure 07: Global Market Absolute $ Opportunity (US$ Million) By Urine Sample Type Segment, 2022 to 2032 Figure 08: Global Market Value (US$ Million) & Y-o-Y Growth (%) By Others (Plasma, Saliva, CSF) Sample Type Segment, 2022 to 2032 Figure 09: Global Market Absolute $ Opportunity (US$ Million) By Others (Plasma, Saliva, CSF) Sample Type Segment, 2022 to 2032 Figure 10: Global Market Share Analysis (%) By Marker Type, 2022 & 2032 Figure 11: Global Market Y-o-Y Growth (%) By Marker Type, 2022 to 2032 Figure 12: Global Market Attractiveness Analysis By Marker Type, 2022 to 2032 Figure 13: Global Market Value (US$ Million) & Y-o-Y Growth (%) By CTCs Marker Type Segment, 2022 to 2032 Figure 14: Global Market Absolute $ Opportunity (US$ Million) By CTCs Marker Type Segment, 2022 to 2032 Figure 15: Global Market Value (US$ Million) & Y-o-Y Growth (%) By CtNA Marker Type Segment, 2022 to 2032 Figure 16: Global Market Absolute $ Opportunity (US$ Million) By ctNA Marker Type Segment, 2022 to 2032 Figure 17: Global Market Value (US$ Million) & Y-o-Y Growth (%) By Exosomes Marker Type Segment, 2022 to 2032 Figure 18: Global Market Absolute $ Opportunity (US$ Million) By Exosomes Marker Type Segment, 2022 to 2032 Figure 19: Global Market Share Analysis (%) By End User, 2022 & 2032 Figure 20: Global Market Y-o-Y Growth (%) By End User, 2022 to 2032 Figure 21: Global Market Attractiveness Analysis By End User, 2022 to 2032 Figure 22: Global Market Value (US$ Million) & Y-o-Y Growth (%) By Hospitals End User Segment, 2022 to 2032 Figure 23: Global Market Absolute $ Opportunity (US$ Million) By Hospitals End User Segment, 2022 to 2032 Figure 24: Global Market Value (US$ Million) & Y-o-Y Growth (%) By Cancer Institutes End User Segment, 2022 to 2032 Figure 25: Global Market Absolute $ Opportunity (US$ Million) By Cancer Institutes End User Segment, 2022 to 2032 Figure 26: Global Market Value (US$ Million) & Y-o-Y Growth (%) By Academic Institutes End User Segment, 2022 to 2032 Figure 27: Global Market Absolute $ Opportunity (US$ Million) By Academic Institutes End User Segment, 2022 to 2032 Figure 28: Global Market Value (US$ Million) & Y-o-Y Growth (%) By Diagnostics Centers End User Segment, 2022 to 2032 Figure 29: Global Market Absolute $ Opportunity (US$ Million) By Diagnostics Centers End User Segment, 2022 to 2032 Figure 30: Global Market Share Analysis (%) By Disease Indication, 2022 & 2032 Figure 31: Global Market Y-o-Y Growth (%) By Disease Indication, 2022 to 2032 Figure 32: Global Market Attractiveness Analysis By Disease Indication, 2022 to 2032 Figure 33: Global Market Value (US$ Million) & Y-o-Y Growth (%) By Lung Cancer Disease Indication Segment, 2022 to 2032 Figure 34: Global Market Absolute $ Opportunity (US$ Million) By Lung Cancer Disease Indication Segment, 2022 to 2032 Figure 35: Global Market Value (US$ Million) & Y-o-Y Growth (%) By Gastrointestinal Cancer Disease Indication Segment, 2022 to 2032 Figure 36: Global Market Absolute $ Opportunity (US$ Million) By Gastrointestinal Cancer Disease Indication Segment, 2022 to 2032 Figure 37: Global Market Value (US$ Million) & Y-o-Y Growth (%) By Prostate Cancer Disease Indication Segment, 2022 to 2032 Figure 38: Global Market Absolute $ Opportunity (US$ Million) By Prostate Cancer Disease Indication Segment, 2022 to 2032 Figure 39: Global Market Value (US$ Million) & Y-o-Y Growth (%) By Breast Cancer Disease Indication Segment, 2022 to 2032 Figure 40: Global Market Absolute $ Opportunity (US$ Million) By Breast Cancer Disease Indication Segment, 2022 to 2032 Figure 41: Global Market Value (US$ Million) & Y-o-Y Growth (%) By Colorectal Cancer Disease Indication Segment, 2022 to 2032 Figure 42: Global Market Absolute $ Opportunity (US$ Million) By Colorectal Cancer Disease Indication Segment, 2022 to 2032 Figure 43: Global Market Value (US$ Million) & Y-o-Y Growth (%) By Leukemia Disease Indication Segment, 2022 to 2032 Figure 44: Global Market Absolute $ Opportunity (US$ Million) By Leukemia Disease Indication Segment, 2022 to 2032 Figure 45: Global Market Value (US$ Million) & Y-o-Y Growth (%) By Others Cancer Disease Indication Segment, 2022 to 2032 Figure 46: Global Market Absolute $ Opportunity (US$ Million) By Others Cancer Disease Indication Segment, 2022 to 2032 Figure 47: Global Market Share Analysis (%) By Region, 2022 & 2032 Figure 48: Global Market Y-o-Y Growth (%) By Region, 2022 to 2032 Figure 49: Global Market Attractiveness Analysis By Region, 2022 to 2032 Figure 50: North America Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 51: North America Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 53: Latin America Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 54: Western Europe Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 55: Western Europe Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 56: Eastern Europe Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 57: Eastern Europe Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 58: APEJ Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 59: APEJ Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 60: Japan Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 61: Japan Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 62: MEA Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 63: MEA Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 64: North America Market Share Analysis (%) By Country, 2022 & 2032 Figure 65: North America Market Y-o-Y Growth (%) By Country, 2022 to 2032 Figure 66: North America Market Attractiveness Analysis By Country, 2022 to 2032 Figure 67: The U.S. Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 68: The U.S. Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 69: Canada Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 70: Canada Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 71: North America Market Attractiveness Analysis By Marker Type, 2022 to 2032 Figure 72: North America Market Attractiveness Analysis By End User, 2022 to 2032 Figure 73: North America Market Attractiveness Analysis By Sample Type, 2022 to 2032 Figure 74: North America Market Attractiveness Analysis By Disease Indication, 2022 to 2032 Figure 75: Latin America Market Share Analysis (%) By Country, 2022 & 2032 Figure 76: Latin America Market Y-o-Y Growth (%) By Country, 2022 to 2032 Figure 77: Latin America Market Attractiveness Analysis By Country, 2022 to 2032 Figure 78: Brazil Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 79: Brazil Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 80: Mexico Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 81: Mexico Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 82: Rest of Latin America Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 83: Rest of Latin America Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 84: Latin America Market Attractiveness Analysis By Marker Type, 2022 to 2032 Figure 85: Latin America Market Attractiveness Analysis By End User, 2022 to 2032 Figure 86: Latin America Market Attractiveness Analysis By Sample Type, 2022 to 2032 Figure 87: Latin America Market Attractiveness Analysis By Disease Indication, 2022 to 2032 Figure 90: Western Europe Market Share Analysis (%) By Country, 2022 & 2032 Figure 91: Western Europe Market Y-o-Y Growth (%) By Country, 2022 to 2032 Figure 92: Western Europe Market Attractiveness Analysis By Country, 2022 to 2032 Figure 93: The U.K Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 94: The U.K Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 95: Germany Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 96: Germany Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 97: France Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 98: France Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 99: Spain the market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 100: Spain the market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 101: Italy Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 102: Italy Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 103: NORDIC Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 104: NORDIC Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 105: BENELUX Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 106: BENELUX Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 107: Rest of Western Europe Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 108: Rest of Western Europe Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 109: Western Europe Market Attractiveness Analysis By Marker Type, 2022 to 2032 Figure 110: Western Europe Market Attractiveness Analysis By End User, 2022 to 2032 Figure 111: Western Europe Market Attractiveness Analysis By Sample Type, 2022 to 2032 Figure 112: Western Europe Market Attractiveness Analysis By Disease Indication, 2022 to 2032 Figure 113: Eastern Europe Market Share Analysis (%) By Country, 2022 & 2032 Figure 114: Eastern Europe Market Y-o-Y Growth (%) By Country, 2022 to 2032 Figure 115: Eastern Europe Market Attractiveness Analysis By Country, 2022 to 2032 Figure 116: Russia Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 117: Russia Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 118: Poland Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 119: Poland Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 120: Rest of Eastern Europe Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 121: Rest of Eastern Europe Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 122: Eastern Europe Market Attractiveness Analysis By Marker Type, 2022 to 2032 Figure 123: Eastern Europe Market Attractiveness Analysis By End User, 2022 to 2032 Figure 124: Eastern Europe Market Attractiveness Analysis By Sample Type, 2022 to 2032 Figure 125: Eastern Europe Market Attractiveness Analysis By Disease Indication, 2022 to 2032 Figure 126: APEJ Market Share Analysis (%) By Country, 2022 & 2032 Figure 127: APEJ Market Y-o-Y Growth (%) By Country, 2022 to 2032 Figure 128: APEJ Market Attractiveness Analysis By Country, 2022 to 2032 Figure 129: China Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 130: China Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 131: India Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 132: India Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 133: Australia & New Zealand Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 134: Australia & New Zealand Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 135: ASEAN Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 136: ASEAN Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 137: Rest of APEJ Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 138: Rest of APEJ Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 139: APEJ Market Attractiveness Analysis By Marker Type, 2022 to 2032 Figure 140: APEJ Market Attractiveness Analysis By End User, 2022 to 2032 Figure 141: APEJ Market Attractiveness Analysis By Sample Type, 2022 to 2032 Figure 142: APEJ Market Attractiveness Analysis By Disease Indication, 2022 to 2032 Figure 145: Japan Market Attractiveness Analysis By Sample Type, 2022 to 2032 Figure 146: Japan Market Attractiveness Analysis By Disease Indication, 2022 to 2032 Figure 143: Japan Market Attractiveness Analysis By Marker Type, 2022 to 2032 Figure 144: Japan Market Attractiveness Analysis By End User, 2022 to 2032 Figure 147: MEA Market Share Analysis (%) By Country, 2022 & 2032 Figure 148: MEA Market Y-o-Y Growth (%) By Country, 2022 to 2032 Figure 149: MEA Market Attractiveness Analysis By Country, 2022 to 2032 Figure 150: GCC Countries Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 151: GCC Countries Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 152: South Africa Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 153: South Africa Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 154: Rest of MEA Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032 Figure 155: Rest of MEA Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 156: MEA Market Attractiveness Analysis By Marker Type, 2022 to 2032 Figure 157: MEA Market Attractiveness Analysis By End User, 2022 to 2032 Figure 158: MEA Market Attractiveness Analysis By Sample Type, 2022 to 2032 Figure 159: MEA Market Attractiveness Analysis By Disease Indication, 2022 to 2032
Recommendations
Explore Healthcare Insights
View Reports
